To include your compound in the COVID-19 Resource Center, submit it here.

AVP-786: Phase II started

Avanir began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily oral AVP-786 for 10 weeks in

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE